Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Arcus Biosciences (RCUS) Accumulated Depreciation & Amortization (2017 - 2025)

Arcus Biosciences has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $10.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $10.0 million, changed 0.0%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $10.0 million at Arcus Biosciences, roughly flat from $10.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for RCUS hit a ceiling of $10.0 million in Q4 2024 and a floor of $4.0 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $8.0 million (2023), compared with a mean of $7.6 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: crashed 72.0% in 2021 and later soared 50.0% in 2022.
  • Arcus Biosciences' Accumulated Depreciation & Amortization stood at $4.0 million in 2021, then soared by 50.0% to $6.0 million in 2022, then soared by 33.33% to $8.0 million in 2023, then increased by 25.0% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $10.0 million (Q4 2025), $10.0 million (Q4 2024), and $8.0 million (Q4 2023) per Business Quant data.